PMVP - NASDAQ
PMV Pharmaceuticals, Inc.
$1.16
-0.43%PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
At a Glance
Live SnapshotPMV Pharmaceuticals, Inc. Management Team
Dr. Deepika Jalota Pharm.D.
Chief Development Officer
Compensation
$638,364
Mr. Michael Carulli
Chief Financial Officer
Compensation
$532,801
Dr. David H. Mack Ph.D.
Co-Founder, Chief Executive Officer, President & Director
Compensation
$943,066
Dr. Arnold J. Levine Ph.D.
Co-Founder, Independent Director & Member of Scientific Advisory Board
Compensation
$140,000
Mr. Robert Ticktin J.D.
General Counsel, Chief Operating Officer & Company Secretary
Dr. Marc Fellous M.D.
Senior Vice President and Head of Clinical Development & Medical Affairs
Mr. Tim Smith
Senior Vice President and Head of Corporate Development & Investor Relations
Dr. Binh Vu Ph.D.
Senior Vice President of Drug Discovery & CMC
Ms. Laura De Leon
Vice President & Head of Clinical Operations
Ms. Crystal Zuckerman
Vice President of Human Resources
PMV Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $159K and sold $2.91M worth of PMVP shares, resulting in $2.75M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
1.7M
2.72M
-2.7M
-$2.72M
9-12 Months
167.5K
159.12K
176.4K
183.93K
-25K
-$25K
Top Buyers
Baum Charles M
Director
$32K
Stelzer Laurie
Director
$32K
Levine Arnold J
Director
$32K
Heyman Richard A.
Director
$32K
Flowers Kirsten
Director
$32K
Top Sellers
Orbimed Advisors Llc
10 Percent Owner
$2.42M
Mack David Henry
Director, Officer: President And Ceo
$364K
Jalota Deepika
Officer: Chief Development Officer
$35K
Gallagher Carol Giltner
Director
$32K
Carulli Michael
Officer: Chief Financial Officer
$30K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $2.75M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
PMVP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 23, 2021 | June 02, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.